About BMF-650 BMF-650 is an investigational, next-generation oral small-molecule GLP-1 RA being developed by Biomea Fusion for the treatment of obesity. Related to the broader orforglipron chemotype, ...

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...

Traws Pharma, Inc. (($TRAW)) announced an update on their ongoing clinical study. Study Overview: Traws Pharma, Inc. is conducting a Phase 1 ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 clinical study titled A Phase 1, ...

Korea’s First Bacteriophage IND Approved by the Ministry of Food and Drug Safety – Phase 1 Trial to Begin in Patients with Acute PneumoniaSEOUL, South Korea, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ...

Monoclonal antibodies (mAbs) contain N-linked glycans that influence pharmacokinetics and efficacy, making glycoform ...

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical stud ...

OncoNano Medicine, Inc. ("OncoNano") announced encouraging first-in-human results from Part 1 of its Phase 1 ON-5001 trial evaluating ONM-501, a dual-acting STING agonist, as monotherapy and in ...

Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven conditionRAPT ...

Corsera Health, Inc., leading the future of cardiovascular health through prediction and prevention, today announced the filing of a clinical trial notification (CTN) to initiate a Phase 1 clinical ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a single-injection, once-mo ...